# US 2026/0062760 A1 · Methods of treatment and diagnosis of multiple myeloma progression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062760 A1
- Document ID: US20260062760A1
- Status: Published application
- Kind: A1
- Application number: 19/353,122
- Filed: 2025-10-08
- Published: 2026-03-05
- Earliest claimed: 2022-04-20
- Assignees: Morehouse School of Medicine
- Applicants: Morehouse School of Medicine
- Inventors: James W. LILLARD, JR.; Olayinka ADEBAYO
- Web page: https://patentgrep.com/patent/US20260062760A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 35/04: specific for metastasis
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating multiple myeloma, comprising administering one or more agents increasing or inhibiting the expression or activity of one or more MM biomarkers to inhibit the progression of multiple myeloma, wherein the one or more MM biomarkers correspond to gene products from one or more of GABRA3, CTAG2, MAGEA6, SOHLH1, MAGEA1, AFAP1-AS1; CBX2, LINC00484, KIF7, TMSB15A, NEK2, NTRK1, CCND2, NES, PKP2, C1orf226, IFITM1, CDH23, AGRN, DHX58, and LINC02576. A method of diagnosing and treating multiple myeloma in a subject comprises, (a) measuring the level of one or more biomarkers in a sample; (b) comparing the level of the one or more biomarkers to a reference level of the one or more biomarkers; (c) making a diagnosis based on the result of the comparing step; and (d) treating the subject with one or more active agents where the subject is diagnosed with multiple myeloma.

## Claims

### Claim 1

A method of diagnosing and treating multiple myeloma (MM) in a subject comprising,
(a) measuring the level of one or more biomarkers in a sample from the subject;
(b) comparing the level of the one or more biomarkers to a reference level of the one or more biomarkers;
(c) making a diagnosis based on the result of the comparing step; and
(d) treating the subject with one or more active agents where the subject is diagnosed with multiple myeloma.

### Claim 2 (depends on 1)

The method of claim 1, comprising measuring the levels of at least 5 MM biomarkers,
wherein the biomarkers are selected from one or more of GABRA3, CTAG2, MAGEA6, SOHLH1, MAGEA1, AFAP1-AS1; CBX2, LINC00484, KIF7, TMSB15A, NEK2, NTRK1, CCND2, NES, PKP2, and C1orf226, and
wherein increased activity or expression of the MM biomarker in the sample as compared to a control is indicative of multiple myeloma.

### Claim 3 (depends on 1)

The method of claim 1, comprising measuring the levels of at least 5 MM biomarkers, wherein the biomarkers are selected from one or more of IFITM1, CDH23, AGRN, DHX58, and LINC02576,
wherein decreased activity or expression of the MM biomarker in the sample as compared to a control is indicative of multiple myeloma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biomarker is GABRA3.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sample comprises blood plasma cells or bone marrow cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sample is a urine sample.

### Claim 7 (depends on 4)

The method of claim 4, comprising administering a GABAA or GABRA3 receptor antagonist.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antagonist is one or more selected from the group consisting of flumazenil, thiocolchicoside, pentetrazol, picrotoxin, topiramate, loreclezole, etomitade and propofol.

### Claim 9 (depends on 7)

The method of claim 7, wherein the antagonist is an antibody directed against the GABAA alpha-3 subunit.

### Claim 10 (depends on 7)

The method of claim 7, wherein the antagonist is a polynucleotide.

### Claim 11 (depends on 10)

The method of claim 10, wherein the polynucleotide is an RNA selected from the group consisting of a short interfering RNA (siRNA), a short hairpin RNA (shRNA) molecule, an antisense RNA, and a microRNA (miRNA).

### Claim 12 (depends on 10)

The method of claim 10, wherein the polynucleotide is an A-to-I RNA edited GABRA3 encoded polynucleotide.

### Claim 13

A method for determining disease progression or risk for metastasis in a subject with multiple myeloma, comprising the steps of:
(a) measuring the level of one or more biomarkers in a first sample obtained from the subject with multiple myeloma at a first time point;
(b) measuring the level of the one or more biomarkers in a second sample obtained from the subject at a second time point;
(c) comparing the level of the one or more biomarkers at the first time point to the level of the one or more biomarkers at the second time point;
(d) determining the disease progression between the first and the second time point based on the result of step (c); and
(e) further treating the subject with one or more active agents if the multiple myeloma has progressed.

### Claim 14

A method for determining the efficacy of a treatment for multiple myeloma in a subject, comprising the steps of:
(a) measuring the level of one or more biomarkers in a first sample obtained from the subject at a first time point;
(b) measuring the level of the one or more biomarkers in a second sample obtained from the subject at a second time point, wherein the subject is under treatment at the second time point;
(c) comparing the level of the one or more biomarkers at the first time point to the level of the one or more biomarkers at the second time point;
(d) determining the efficacy of the treatment based on the result of step (c); and
(e) further treating the subject with one or more active agents if the efficacy has been found to be insufficient for treatment. In certain preferred embodiments, the one or more active agents in step (e) include one or more active agents that were not administered in the previous treatment.

### Claim 15 (depends on 1)

The method of diagnosing and treating of claim 1, wherein the treatment comprises administering to a subject in need thereof, one or more agents increasing or inhibiting the expression or activity of one or more MM biomarkers in amounts sufficient to inhibit the progression of multiple myeloma in the subject,
wherein the one or more MM biomarkers correspond to gene products selected from one or more of GABRA3, CTAG2, MAGEA6, SOHLH1, MAGEA1, AFAP1-AS1; CBX2, LINC00484, KIF7, TMSB15A, NEK2, NTRK1, CCND2, NES, PKP2, C1orf226, IFITM1, CDH23, AGRN, DHX58, and LINC02576.

### Claim 16 (depends on 15)

The method of claim 15, wherein the one or more agents inhibit the expression or activity of biomarker marker identified from one or more of GABRA3, CTAG2, MAGEA6, SOHLH1, MAGEA1, AFAP1-AS1; CBX2, LINC00484, KIF7, TMSB15A, NEK2, NTRK1, CCND2, NES, PKP2, and C1orf226.

### Claim 17 (depends on 15)

The method of claim 15, wherein the one or more agents increase the expression or activity of biomarker marker selected from one or more of IFITM1, CDH23, AGRN, DHX58, and LINC02576.

### Claim 18 (depends on 16)

The method of claim 16, wherein the one or more agents comprise a small molecule GABAA or GABRA3 receptor antagonist selected from the group consisting of flumazenil, thiocolchicoside, pentetrazol, picrotoxin, topiramate, loreclezole, etomitade and propofol.

### Claim 19 (depends on 16)

The method of claim 16, wherein the one or more agents comprise an antibody directed against the GABAA alpha-3 subunit.

### Claim 20 (depends on 13)

The method of claim 13, wherein the one or more agents comprise an RNA selected from the group consisting of short interfering RNA (siRNA), short hairpin RNA (shRNA) molecule, antisense RNA, and microRNA (miRNA).
